Thalia Therapeutics plc Sustainability Reports
Thalia Therapeutics plc is a biotechnology company focused on developing innovative RNA therapeutics and novel delivery systems. The company develops a proprietary delivery platform named Nuvec to target unmet needs in oncology and cardiovascular treatments.
Sector: Professional & technical services
Country: United Kingdom
Exchange: London Stock Exchange (AIM)
ISIN: GB00BYW8QM32
11 reports from 2014 to 2025
- Thalia Therapeutics plc 2025 Annual Report and Consolidated Financial Statements
- Thalia Therapeutics plc 2024 Annual Report and Consolidated Financial Statements
- Thalia Therapeutics plc 2023 Annual Report and Consolidated Financial Statements
- Thalia Therapeutics plc 2022 Annual Report and Consolidated Financial Statements
- Thalia Therapeutics plc 2021 Annual Report and Consolidated Financial Statements